Breast surgeons at the forefront: preserving lymph nodes for enhanced immunotherapy efficacy

References

1. 1.↵
   2. Gentilini OD,
   3. Botteri E,
   4. Sangalli C,
   5. Galimberti V,
   6. Porpiglia M,
   7. Agresti R, et al.

   Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023; 9: 1557–64.

   OpenUrl
2. 2.↵
   2. Li JJ,
   3. Cheng JY,
   4. Liu GY,
   5. Hou YF,
   6. Di GH,
   7. Yang BL, et al.

   Feasibility of sentinel lymph node biopsy omission after integration of ¹⁸F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial. Cancer Biol Med. 2022; 19: 1100–8.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   2. Poortmans P.

   Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014; 383: 2104–6.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Cortes J,
   3. Cescon DW,
   4. Rugo HS,
   5. Nowecki Z,
   6. Im SA,
   7. Yusof MM, et al.

   Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396: 1817–28.

   OpenUrlCrossRefPubMed
5. 5.
   2. Schmid P,
   3. Rugo HS,
   4. Adams S,
   5. Schneeweiss A,
   6. Barrios CH,
   7. Iwata H, et al.

   Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21: 44–59.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Emens LA,
   3. Adams S,
   4. Barrios CH,
   5. Diéras V,
   6. Iwata H,
   7. Loi S, et al.

   First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021; 32: 983–93.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Miles D,
   3. Gligorov J,
   4. André F,
   5. Cameron D,
   6. Schneeweiss A,
   7. Barrios C, et al.

   Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32: 994–1004.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Schmid P,
   3. Cortes J,
   4. Pusztai L,
   5. McArthur H,
   6. Kümmel S,
   7. Bergh J, et al.

   Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382: 810–21.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Schmid P,
   3. Cortes J,
   4. Dent R,
   5. Pusztai L,
   6. McArthur H,
   7. Kümmel S, et al.

   Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022; 386: 556–67.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Ignatiadis M,
    3. Bailey A,
    4. McArthur H,
    5. El-Abed S,
    6. de Azambuja E,
    7. Metzger O, et al.

    Abstract GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial. Cancer Res. 2024: 84: GS01-03.
11. 11.↵
    2. Rahim MK,
    3. Okholm TLH,
    4. Jones KB,
    5. McCarthy EE,
    6. Liu CC,
    7. Yee JL, et al.

    Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023; 186: 1127–43.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Qiu PF,
    3. Wang XE,
    4. Wang YS.

    Indications for individual internal mammary node irradiation. Lancet Oncol. 2021; 22: e40.
13. 13.↵
    2. du Bois H,
    3. Heim TA,
    4. Lund AW.

    Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci Immunol. 2021; 6: eabg3551.